144 related articles for article (PubMed ID: 31017465)
1. Optimisation and usefulness of quantitative analysis of
Fakhry-Darian D; Patel NH; Khan S; Barwick T; Svensson W; Khan S; Perry RJ; Malhotra P; Carswell CJ; Nijran KS; Win Z
Br J Radiol; 2019 Sep; 92(1101):20181020. PubMed ID: 31017465
[TBL] [Abstract][Full Text] [Related]
2. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
[TBL] [Abstract][Full Text] [Related]
3. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
[TBL] [Abstract][Full Text] [Related]
4. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
5. Quantification of 18F-florbetapir PET: comparison of two analysis methods.
Hutton C; Declerck J; Mintun MA; Pontecorvo MJ; Devous MD; Joshi AD;
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):725-32. PubMed ID: 25652817
[TBL] [Abstract][Full Text] [Related]
6. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.
Newberg AB; Arnold SE; Wintering N; Rovner BW; Alavi A
J Nucl Med; 2012 Jun; 53(6):902-7. PubMed ID: 22577238
[TBL] [Abstract][Full Text] [Related]
7. Quantification of [
Golla SS; Verfaillie SC; Boellaard R; Adriaanse SM; Zwan MD; Schuit RC; Timmers T; Groot C; Schober P; Scheltens P; van der Flier WM; Windhorst AD; van Berckel BN; Lammertsma AA
J Cereb Blood Flow Metab; 2019 Nov; 39(11):2172-2180. PubMed ID: 29897009
[TBL] [Abstract][Full Text] [Related]
8. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
10. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
[TBL] [Abstract][Full Text] [Related]
12. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
[TBL] [Abstract][Full Text] [Related]
13. Repeatability of parametric methods for [
Verfaillie SC; Golla SS; Timmers T; Tuncel H; van der Weijden CW; Schober P; Schuit RC; van der Flier WM; Windhorst AD; Lammertsma AA; van Berckel BN; Boellaard R
J Cereb Blood Flow Metab; 2021 Mar; 41(3):569-578. PubMed ID: 32321347
[TBL] [Abstract][Full Text] [Related]
14. Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation.
Nayate AP; Dubroff JG; Schmitt JE; Nasrallah I; Kishore R; Mankoff D; Pryma DA;
AJNR Am J Neuroradiol; 2015 Jul; 36(7):1237-44. PubMed ID: 25767185
[TBL] [Abstract][Full Text] [Related]
15. Optimized classification of
Bullich S; Seibyl J; Catafau AM; Jovalekic A; Koglin N; Barthel H; Sabri O; De Santi S
Neuroimage Clin; 2017; 15():325-332. PubMed ID: 28560157
[TBL] [Abstract][Full Text] [Related]
16. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM;
J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091
[TBL] [Abstract][Full Text] [Related]
17. Use of florbetapir-PET for imaging beta-amyloid pathology.
Clark CM; Schneider JA; Bedell BJ; Beach TG; Bilker WB; Mintun MA; Pontecorvo MJ; Hefti F; Carpenter AP; Flitter ML; Krautkramer MJ; Kung HF; Coleman RE; Doraiswamy PM; Fleisher AS; Sabbagh MN; Sadowsky CH; Reiman EP; Zehntner SP; Skovronsky DM;
JAMA; 2011 Jan; 305(3):275-83. PubMed ID: 21245183
[TBL] [Abstract][Full Text] [Related]
18. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
19. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
[TBL] [Abstract][Full Text] [Related]
20. Classification of negative and positive
de Vries BM; Golla SSV; Ebenau J; Verfaillie SCJ; Timmers T; Heeman F; Cysouw MCF; van Berckel BNM; van der Flier WM; Yaqub M; Boellaard R;
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):721-728. PubMed ID: 32875431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
